Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
ARCHIVE Hisamitsu Licenses Keto Patch to Sigma-Tau in Italy
October 21, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 21, 2002
-
ARCHIVE Asahi Kasei to Spin Off 7 Divisions in October 2003
October 21, 2002
-
ARCHIVE The 3rd Kitasato Harvard Symposium Focuses on Global Drug Development
October 21, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF -1-
October 21, 2002
-
ARCHIVE Drug Organization Gives Grants to 5 Basic Research Projects
October 21, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF -2-
October 21, 2002
-
ARCHIVE Hac-Kimisawa: Semi-annual Consolidated Sales Up 4.4%
October 21, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
October 21, 2002
-
ARCHIVE Kirindo: Sales, Profits Up in 1st Half
October 21, 2002
-
ARCHIVE Drugs Not Requiring Manufacturing or Import Approval Revised
October 21, 2002
-
ARCHIVE Terumo to Acquire Vascutek of Scotland
October 21, 2002
-
ARCHIVE PFSB to Put Top Priory on Post-marketing Safety
October 21, 2002
-
ARCHIVE Olympus to Provide Contents for WebSurg's Online Telesurgery Training Site
October 21, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 21, 2002
-
ARCHIVE Toshiba Corp, Toshiba Medical: Architect c8000
October 21, 2002
-
ARCHIVE BULLETIN
October 21, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
October 21, 2002
-
ARCHIVE The 61st Annual Meeting of the Japanese Cancer Associarion
October 21, 2002
-
ARCHIVE 21st IFPMA Assembly Held in Berlin
October 21, 2002
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…